NCT01529554 - Controlled Level EVERolimus in Acute Coronary Syndromes | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

January 8, 2015

Primary Completion Date

November 29, 2021

Study Completion Date

November 29, 2021

Conditions

Acute Coronary Syndromes

Interventions

DRUG

Everolimus

(d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)

DRUG

Placebo

matched placebo tablets manufactured to be identical to verum tablets except content of everolimus

Trial Locations (8)

Kerckhoff-Klinik, Department of Cardiology, Bad Nauheim

University Hospital Chartié, Berlin

University Hospital Duesseldorf, Düsseldorf

University Hospital Mainz, Mainz

University Hospital Bern, Bern

University Hospital Geneva, Geneva

Cardiocentro Ticino, Lugano

University Hospital Zurich, Zurich